论文部分内容阅读
目的探讨血清细胞因子尿激酶型纤溶酶原激活剂受体(urokinase-type plasminogen activator receptor,uPAR)与小细胞肺癌(small cell lung cancer,SCLC)患者化疗疗效及预后的关系。方法使用酶联免疫吸附法(ELISA)检测80例SCLC患者在化疗前后血清中的uPAR,分析其表达水平与患者疗效及预后的关系。结果化疗前后的小细胞肺癌患者,血清uPAR水平存在明显差异(P<0.05),Kaplan-Meier分析显示uPAR水平的高低与患者预后显著相关(P<0.05),uPAR水平高(>2.057μg/L)的患者中位生存时间为13.3个月,uPAR水平低(≤2.057μg/L)的患者中位生存时间为21.5个月。COX比例风险模型分析结果显示,uPAR可能是判断SCLC患者生存的独立预后因素(P<0.05)。结论 SCLC患者血清uPAR升高提示预后较差,uPAR表达水平的变化可作为SCLC患者化疗疗效的参考指标。
Objective To investigate the relationship between the efficacy of chemotherapy and prognosis of urokinase-type plasminogen activator receptor (uPAR) in patients with small cell lung cancer (SCLC). Methods The levels of uPAR in serum of 80 patients with SCLC before and after chemotherapy were detected by enzyme-linked immunosorbent assay (ELISA), and the relationship between the expression and clinical efficacy and prognosis was analyzed. Results The level of uPAR in patients with small cell lung cancer before and after chemotherapy was significantly different (P <0.05). Kaplan-Meier analysis showed that the level of uPAR was significantly correlated with the prognosis of patients (P <0.05) ) Had a median survival of 13.3 months and a median survival time of 21.5 months for patients with low uPAR levels (≤ 2.057 μg / L). COX proportional hazards model analysis showed that uPAR may be an independent prognostic factor for survival of patients with SCLC (P <0.05). Conclusion The increase of serum uPAR in patients with SCLC suggests that the prognosis is poor. The changes of uPAR expression level may be used as a reference index for the treatment of patients with SCLC.